Aerska's AOC "brain shuttle" targets systemic CNS delivery, reshaping landscape for Avidity Biosciences

AOC brain-delivery push signals industry shift

Aerska is advancing antibody‑oligonucleotide conjugates (AOCs) with a "brain shuttle" designed to overcome the blood–brain barrier, a move that reshapes the competitive and collaborative landscape for firms developing targeted RNA therapeutics such as Avidity Biosciences. The company is positioning systemic intravenous and subcutaneous dosing as a path to uniform, deep brain distribution and durable RNA interference (RNAi) — objectives long sought by oligonucleotide developers who have struggled to reach central nervous system (CNS) targets safely and at scale. For companies like Avidity, which pioneered AOC approaches for peripheral tissues, Aerska’s focus on CNS delivery highlights both a technological inflection point and a potential avenue for cross‑platform partnerships.

The technical premise is simple but consequential: combine antibody targeting with oligonucleotide payloads to ferry RNAi agents across the blood–brain barrier and achieve knockdown in deep brain regions. If Aerska’s brain shuttle meets preclinical and early clinical benchmarks for distribution, safety and durability, it validates a delivery modality that could enable disease‑modifying treatments for genetically driven forms of Alzheimer’s and other neurodegenerative disorders. That outcome raises the bar for AOC developers across the sector to demonstrate systemic dosing, consistent target engagement and acceptable regulatory safety profiles in tissues with high clinical unmet need.

For Avidity Biosciences, the development underscores both opportunity and competition. The company’s experience in antibody‑linked oligonucleotides and systemic delivery to muscle tissues makes it a potential collaborator or comparator as CNS‑targeted AOCs move toward the clinic. Investors and partners in the oligonucleotide field will be watching readouts on brain distribution and durability closely, since validated CNS delivery could accelerate partnership activity, broaden therapeutic indications for AOCs and influence development priorities among platform companies.

Capital backing to advance clinic readiness

EQT Life Sciences’ LSP Dementia Fund leads a USD 39 million Series A in Aerska, co‑led with age1 and joined by laso Ventures and existing investors, bringing Aerska’s total raised to about USD 60 million. The financing is explicitly earmarked to push the AOC brain shuttle toward clinical testing and to support IV and SC dosing strategies aimed at regulatory and commercial viability.

Patient and partnership implications

Developers frame the approach as opening upstream, disease‑modifying interventions that could preserve cognition and quality of life for affected families. For the broader oligonucleotide industry, success in systemic CNS delivery promises to unlock new neurological indications and stimulate collaborations between platform pioneers such as Avidity and emerging CNS specialists like Aerska.